Villaris Therapeutics

Incyte pays out $70M to get hands on Medicxi-backed vitiligo biotech
Endpoints
Mon, 10/3/22 - 10:21 am
Incyte
M&A
Villaris Therapeutics
vitiligo
Medicxi